<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34830303</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>22</Issue><PubDate><Year>2021</Year><Month>Nov</Month><Day>17</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immunomodulation and Regenerative Capacity of MSCs for Long-COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">12421</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms222212421</ELocationID><Abstract><AbstractText>The rapid mutation of the SARS-CoV-2 virus is now a major concern with no effective drugs and treatments. The severity of the disease is linked to the induction of a cytokine storm that promotes extensive inflammation in the lung, leading to many acute lung injuries, pulmonary edema, and eventually death. Mesenchymal stem cells (MSCs) might prove to be a treatment option as they have immunomodulation and regenerative properties. Clinical trials utilizing MSCs in treating acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) have provided a basis in treating post-COVID-19 patients. In this review, we discussed the effects of MSCs as an immunomodulator to reduce the severity and death in patients with COVID-19, including the usage of MSCs as an alternative regenerative therapy in post-COVID-19 patients. This review also includes the current clinical trials in utilizing MSCs and their potential future utilization for long-COVID treatments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Loke</LastName><ForeName>Xin Ya</ForeName><Initials>XY</Initials><Identifier Source="ORCID">0000-0003-0272-2018</Identifier><AffiliationInfo><Affiliation>Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imran</LastName><ForeName>Siti A M</ForeName><Initials>SAM</Initials><AffiliationInfo><Affiliation>Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tye</LastName><ForeName>Gee Jun</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0002-6707-9505</Identifier><AffiliationInfo><Affiliation>Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia, Gelugor 11800, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan Kamarul Zaman</LastName><ForeName>Wan Safwani</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Innovation in Medical Engineering (CIME), Department of Biomedical Engineering, Faculty of Engineering, Universiti Malaya, Kuala Lumpur 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordin</LastName><ForeName>Fazlina</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7053-4580</Identifier><AffiliationInfo><Affiliation>Centre for Tissue Engineering and Regenerative Medicine (CTERM), Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, Cheras, Kuala Lumpur 56000, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FF-2021-378</GrantID><Agency>National University of Malaysia</Agency><Country/></Grant><Grant><GrantID>FPR-1</GrantID><Agency>National University of Malaysia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">MSCs</Keyword><Keyword MajorTopicYN="N">immunomodulation</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">regeneration</Keyword></KeywordList><CoiStatement>The authors declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>27</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34830303</ArticleId><ArticleId IdType="pmc">PMC8625432</ArticleId><ArticleId IdType="doi">10.3390/ijms222212421</ArticleId><ArticleId IdType="pii">ijms222212421</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data. 2021.  [(accessed on 2 September 2021)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Elengoe A. COVID-19 outbreak in Malaysia. Osong Public Health Res. Perspect. J. 2020;11:93&#x2013;100. doi: 10.24171/j.phrp.2020.11.3.08.</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2020.11.3.08</ArticleId><ArticleId IdType="pmc">PMC7258884</ArticleId><ArticleId IdType="pubmed">32494567</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y.C., Chen C.S., Chan Y.J. The outbreak of COVID-19: An overview. J. Chin. Med. Assoc. 2020;83:217&#x2013;220. doi: 10.1097/JCMA.0000000000000270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000270</ArticleId><ArticleId IdType="pmc">PMC7153464</ArticleId><ArticleId IdType="pubmed">32134861</ArticleId></ArticleIdList></Reference><Reference><Citation>Cucinotta D., Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91:157&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569573</ArticleId><ArticleId IdType="pubmed">32191675</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Pandemic, Declared by the World Health Organization (WHO) Mar 12, 2020.  [(accessed on 3 August 2021)].  Available online:  https://www.pharmaceutical-technology.com/news/who-declares-covid-19-pandemic/</Citation></Reference><Reference><Citation>&#xc7;etin &#x130;., Top&#xe7;ul M. Can mesenchymal stem cells be used to treat COVID-19-induced pneumonia? Biomed. Rep. 2020;13:62. doi: 10.3892/br.2020.1369.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2020.1369</ArticleId><ArticleId IdType="pmc">PMC7657083</ArticleId><ArticleId IdType="pubmed">33194191</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers of Disease Control and Prevention  How to Protect Yourself &amp; Others.  [(accessed on 3 August 2021)];2021 August 13; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html.</Citation></Reference><Reference><Citation>How Ventilators Help with Severe COVID-19 Symptoms. Jun 8, 2020.  [(accessed on 3 August 2021)].  Available online:  https://www.uchealth.com/en/media-room/covid-19/ventilators-and-covid-19.</Citation></Reference><Reference><Citation>Banerjee S. COVID-19: Variants of Concern and Variants of Interest. Jul 13, 2021.  [(accessed on 3 August 2021)].  Available online:  https://www.thehindu.com/sci-tech/health/covid-19-variants-of-concern-and-variants-of-interest/article35301681.ece.</Citation></Reference><Reference><Citation>World Health Organization  Tracking SARS-CoV-2 Variants.  [(accessed on 3 August 2021)].  Available online:  https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</Citation></Reference><Reference><Citation>Boopathi S., Poma A.B., Kolandaivel P. Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. J. Biomol. Struct. Dyn. 2021;39:3409&#x2013;3418. doi: 10.1080/07391102.2020.1758788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07391102.2020.1758788</ArticleId><ArticleId IdType="pmc">PMC7196923</ArticleId><ArticleId IdType="pubmed">32306836</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and t cellreplication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155&#x2013;170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V., Doshi K.U., Khan W.H., Rathore A.S. COVID-19 pandemic: Mechanism, diagnosis, and treatment. J. Chem. Technol. Biotechnol. 2021;96:299&#x2013;308. doi: 10.1002/jctb.6641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jctb.6641</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin P., Wang M., Wei Y., Kim T., Wei X. Coronavirus in human diseases, mechanisms and advances in clinical treatment. MedComm. 2020;1:270&#x2013;301. doi: 10.1002/mco2.26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.26</ArticleId><ArticleId IdType="pmc">PMC7646666</ArticleId><ArticleId IdType="pubmed">33173860</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA. 2005;102:11876&#x2013;11881. doi: 10.1073/pnas.0505577102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505577102</ArticleId><ArticleId IdType="pmc">PMC1188015</ArticleId><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Coelho A., Alvites R.D., Branquinho M.V., Guerreiro S.G., Maur&#xed;cio A.C. Mesenchymal stem cells (MSCs) as a potential therapeutic strategy in COVID-19 patients: Literature research. Front. Cell Dev. Biol. 2020;8:602647. doi: 10.3389/fcell.2020.602647.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.602647</ArticleId><ArticleId IdType="pmc">PMC7710935</ArticleId><ArticleId IdType="pubmed">33330498</ArticleId></ArticleIdList></Reference><Reference><Citation>Moll G., Drzeniek N., Kamhieh-Milz J., Geissler S., Volk H.D., Reinke P. MSC therapies for COVID-19: Importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front. Immunol. 2020;11:1091. doi: 10.3389/fimmu.2020.01091.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01091</ArticleId><ArticleId IdType="pmc">PMC7249852</ArticleId><ArticleId IdType="pubmed">32574263</ArticleId></ArticleIdList></Reference><Reference><Citation>Reardon S. The Most Worrying Mutations in Five Emerging Coronavirus Variants&#x2014;Scientific American. Jan 29, 2021.  [(accessed on 5 August 2021)].  Available online:  https://www.scientificamerican.com/article/the-most-worrying-mutations-in-five-emerging-coronavirus-variants/</Citation></Reference><Reference><Citation>Haider N., Rothman-Ostrow P., Osman A.Y., Arruda L.B., Macfarlane-Berry L., Elton L., Thomason M.J., Yeboah-Manu D., Ansumana R., Kapata N., et al. COVID-19&#x2014;zoonosis or emerging infectious disease? Front. Public Health. 2020;8:596944. doi: 10.3389/fpubh.2020.596944.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.596944</ArticleId><ArticleId IdType="pmc">PMC7725765</ArticleId><ArticleId IdType="pubmed">33324602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupferschmidt K. New mutations raise specter of &#x2018;immune escape&#x2019;. Science. 2021;371:329&#x2013;330. doi: 10.1126/science.371.6527.329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.371.6527.329</ArticleId><ArticleId IdType="pubmed">33479129</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayres J.S. Surviving COVID-19: A disease tolerance perspective. Sci. Adv. 2020;6:4&#x2013;6. doi: 10.1126/sciadv.abc1518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc1518</ArticleId><ArticleId IdType="pmc">PMC7190329</ArticleId><ArticleId IdType="pubmed">32494691</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelzman F. COVID-19 and Disease Severity: Why Is There Such a Wide Range?  [(accessed on 7 August 2021)].  Available online:  https://healthmatters.nyp.org/covid-19-and-disease-severity/</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Older Adults Risks and Vaccine Information.  [(accessed on 8 August 2021)]; Available online:  https://www.cdc.gov/aging/covid19/covid19-older-adults.html.</Citation></Reference><Reference><Citation>Chen P.L., Lee N.Y., Cia C.T., Ko W.C., Hsueh P.R. A review of treatment of coronavirus disease 2019 (COVID-19): Therapeutic repurposing and unmet clinical needs. Front. Pharmacol. 2020;11:584956. doi: 10.3389/fphar.2020.584956.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.584956</ArticleId><ArticleId IdType="pmc">PMC7751753</ArticleId><ArticleId IdType="pubmed">33364959</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha R.P., Sharma A.R., Singh M.K., Samanta S., Bhakta S., Mandal S., Bhattacharya M., Lee S.S., Chakraborty C. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front. Pharmacol. 2020;11:1258. doi: 10.3389/fphar.2020.01258.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01258</ArticleId><ArticleId IdType="pmc">PMC7466451</ArticleId><ArticleId IdType="pubmed">32973505</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Food and Drug Administration  Comirnaty and Pfizer-BioNTech Storm COVID-19 Vaccine.  [(accessed on 10 August 2021)]; Available online:  https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine.</Citation></Reference><Reference><Citation>World Health Organization  Vaccine Efficacy, Effectiveness and Protection.  [(accessed on 10 August 2021)].  Available online:  https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection.</Citation></Reference><Reference><Citation>Cuffari B. What Is a Cytokine Storm?  [(accessed on 10 August 2021)].  Available online:  https://www.news-medical.net/health/What-is-Cytokine-Storm.aspx.</Citation></Reference><Reference><Citation>Coperchini F., Chiovato L., Croce L., Magri F., Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25&#x2013;32. doi: 10.1016/j.cytogfr.2020.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.05.003</ArticleId><ArticleId IdType="pmc">PMC7211650</ArticleId><ArticleId IdType="pubmed">32446778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tisoncik J.R., Korth M.J., Simmons C.P., Farrar J., Martin T.R., Katze M.G. Into the eye of the cytokine storm. Microbiol. Mol. Biol. Rev. 2012;76:16&#x2013;32. doi: 10.1128/MMBR.05015-11.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.05015-11</ArticleId><ArticleId IdType="pmc">PMC3294426</ArticleId><ArticleId IdType="pubmed">22390970</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int. J. Antimicrob. Agents. 2020;55:105982. doi: 10.1016/j.ijantimicag.2020.105982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105982</ArticleId><ArticleId IdType="pmc">PMC7161506</ArticleId><ArticleId IdType="pubmed">32305588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 cytokine storm; what we know so far. Front. Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Wang F., Huang Z., Wu Y., Geng J., Wang Y. Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An update and concise review. Int. J. Med. Sci. 2021;18:2849&#x2013;2870. doi: 10.7150/ijms.59218.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijms.59218</ArticleId><ArticleId IdType="pmc">PMC8241779</ArticleId><ArticleId IdType="pubmed">34220313</ArticleId></ArticleIdList></Reference><Reference><Citation>Costela-Ruiz V.J., Illescas-Montes R., Puerta-Puerta J.M., Ruiz C., Melguizo-Rodr&#xed;guez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62&#x2013;75. doi: 10.1016/j.cytogfr.2020.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2020.06.001</ArticleId><ArticleId IdType="pmc">PMC7265853</ArticleId><ArticleId IdType="pubmed">32513566</ArticleId></ArticleIdList></Reference><Reference><Citation>Van De Veerdonk F.L., Netea M.G. Blocking IL-1 to prevent respiratory failure in COVID-19. Crit. Care. 2020;24:445. doi: 10.1186/s13054-020-03166-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03166-0</ArticleId><ArticleId IdType="pmc">PMC7411343</ArticleId><ArticleId IdType="pubmed">32682440</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine storm. N. Engl. J. Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronstein B.N. Interleukin-6&#x2014;A key mediator of systemic and local symptoms in rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 2007;65((Suppl. 1)):S11&#x2013;S15.</Citation><ArticleIdList><ArticleId IdType="pubmed">17708739</ArticleId></ArticleIdList></Reference><Reference><Citation>Darif D., Hammi I., Kihel A., El Idrissi Saik I., Guessous F., Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb. Pathog. 2021;153:104799. doi: 10.1016/j.micpath.2021.104799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2021.104799</ArticleId><ArticleId IdType="pmc">PMC7889464</ArticleId><ArticleId IdType="pubmed">33609650</ArticleId></ArticleIdList></Reference><Reference><Citation>Song P., Li W., Xie J., Hou Y., You C. Cytokine storm induced by SARS-CoV-2. Clin. Chim. Acta. 2020;509:280&#x2013;287. doi: 10.1016/j.cca.2020.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.06.017</ArticleId><ArticleId IdType="pmc">PMC7283076</ArticleId><ArticleId IdType="pubmed">32531256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawson B.R., Gonzalez-Quintial R., Eleftheriadis T., Farrar M.A., Miller S.D., Sauer K., McGavern D.B., Kono D.H., Baccala R., Theofilopoulos A.N. Interleukin-7 is required for CD4 + T cell activation and autoimmune neuroinflammation. Clin. Immunol. 2015;161:260&#x2013;269. doi: 10.1016/j.clim.2015.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2015.08.007</ArticleId><ArticleId IdType="pmc">PMC4658267</ArticleId><ArticleId IdType="pubmed">26319414</ArticleId></ArticleIdList></Reference><Reference><Citation>Azmi N.U., Puteri M.U., Lukmanto D. Cytokine storm in COVID-19: An overview, mechanism, treatment strategies, and stem cell therapy perspective. Pharm. Sci. Res. 2020;7:1&#x2013;11. doi: 10.7454/psr.v7i4.1092.</Citation><ArticleIdList><ArticleId IdType="doi">10.7454/psr.v7i4.1092</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorelik L., Constant S., Flavell R.A. Mechanism of transforming growth factor &#x3b2;-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 2002;195:1499&#x2013;1505. doi: 10.1084/jem.20012076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20012076</ArticleId><ArticleId IdType="pmc">PMC2193549</ArticleId><ArticleId IdType="pubmed">12045248</ArticleId></ArticleIdList></Reference><Reference><Citation>Burleson S.C.M., Fick R.B., Mannie M.D., Olmstead S.G., Van Scott M.R. Chapter 35&#x2014;the immune basis of allergic lung disease. In: Parent R., editor. Comparative Biology of the Normal Lung. 2nd ed. Academic Press; Cambridge, MA, USA: 2005. pp. 683&#x2013;719.</Citation></Reference><Reference><Citation>Shiomi A., Usui T. Pivotal roles of GM-CSF in autoimmunity and inflammation. Mediat. Inflamm. 2015;2015:568543. doi: 10.1155/2015/568543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/568543</ArticleId><ArticleId IdType="pmc">PMC4370199</ArticleId><ArticleId IdType="pubmed">25838639</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudlak K., Demuro J.P., Hanna A.F., Brem H. Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor. Int. J. Crit. Illn. Inj. Sci. 2013;3:279&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3891197</ArticleId><ArticleId IdType="pubmed">24459628</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang K.J., Su I.J., Theron M., Wu Y.C., Lai S.K., Liu C.C., Lei H.Y. An interferon-&#x3b3;-related cytokine storm in SARS patients. J. Med. Virol. 2005;75:185&#x2013;194. doi: 10.1002/jmv.20255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.20255</ArticleId><ArticleId IdType="pmc">PMC7166886</ArticleId><ArticleId IdType="pubmed">15602737</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyerowitz E.A., Sen P., Schoenfeld S.R., Neilan T.G., Frigault M.J., Stone J.H., Kim A.Y., Mansour M.K. Immunomodulation as treatment for severe coronavirus disease 2019: A systematic review of current modalities and future directions. Clin. Infect. Dis. 2021;72:E1130&#x2013;E1143. doi: 10.1093/cid/ciaa1759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1759</ArticleId><ArticleId IdType="pmc">PMC7717185</ArticleId><ArticleId IdType="pubmed">33216852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Chen Y., Meng Z. Immunomodulation for severe COVID-19 pneumonia: The state of the art. Front. Immunol. 2020;11:2782. doi: 10.3389/fimmu.2020.577442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.577442</ArticleId><ArticleId IdType="pmc">PMC7680845</ArticleId><ArticleId IdType="pubmed">33240265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Q., Wang B., Mao J. The pathogenesis and treatment of the &#x2018;cytokine storm&#x2019;&#x2019; in COVID-19. J. Infect. 2020;80:607&#x2013;613. doi: 10.1016/j.jinf.2020.03.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.037</ArticleId><ArticleId IdType="pmc">PMC7194613</ArticleId><ArticleId IdType="pubmed">32283152</ArticleId></ArticleIdList></Reference><Reference><Citation>Song N., Wakimoto H., Rossignoli F., Bhere D., Ciccocioppo R., Chen K.S., Khalsa J.K., Mastrolia I., Samarelli A.V., Dominici M., et al. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm. Stem Cells. 2021;39:707&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014246</ArticleId><ArticleId IdType="pubmed">33586320</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss A.R.R., Dahlke M.H. Immunomodulation by mesenchymal stem cells (MSCs): Mechanisms of action of living, apoptotic, and dead MSCs. Front. Immunol. 2019;10:1191. doi: 10.3389/fimmu.2019.01191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01191</ArticleId><ArticleId IdType="pmc">PMC6557979</ArticleId><ArticleId IdType="pubmed">31214172</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury M.A., Hossain N., Kashem M.A., Shahid M.A., Alam A. Immune response in COVID-19: A review. J. Infect. Public Health. 2020;13:1619&#x2013;1629. doi: 10.1016/j.jiph.2020.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.07.001</ArticleId><ArticleId IdType="pmc">PMC7359800</ArticleId><ArticleId IdType="pubmed">32718895</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavianpour M., Saleh M., Verdi J. The role of mesenchymal stromal cells in immune modulation of COVID-19: Focus on cytokine storm. Stem Cell Res. Ther. 2020;11:404. doi: 10.1186/s13287-020-01849-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01849-7</ArticleId><ArticleId IdType="pmc">PMC7499002</ArticleId><ArticleId IdType="pubmed">32948252</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  What We Know About the COVID-19 Immune Response: The Latest in COVID-19 Immunity &amp; the Current Global Situation. 2020.  [(accessed on 15 August 2021)].  Available online:  https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update-34-immunity-2nd.pdf?sfvrsn=8a488cb6_2.</Citation></Reference><Reference><Citation>Verma Y.K., Verma R., Tyagi N., Behl A., Kumar S., Gangenahalli G.U. COVID-19 and its therapeutics: Special emphasis on mesenchymal stem cells based therapy. Stem Cell Rev. Rep. 2021;17:113&#x2013;131. doi: 10.1007/s12015-020-10037-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-020-10037-2</ArticleId><ArticleId IdType="pmc">PMC7486977</ArticleId><ArticleId IdType="pubmed">32920752</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppert L.A., Matthay M.A. Alveolar fluid clearance in pathologically relevant conditions: In vitro and in vivo models of acute respiratory distress syndrome. Front. Immunol. 2017;8:371. doi: 10.3389/fimmu.2017.00371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00371</ArticleId><ArticleId IdType="pmc">PMC5383664</ArticleId><ArticleId IdType="pubmed">28439268</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi S., Soudi S., Shafiee A., Hashemi S.M. Mesenchymal stem cell therapies for COVID-19: Current status and mechanism of action. Life Sci. 2020;262:118493. doi: 10.1016/j.lfs.2020.118493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118493</ArticleId><ArticleId IdType="pmc">PMC7510562</ArticleId><ArticleId IdType="pubmed">32979360</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeyaraman M., John A., Koshy S., Ranjan R., Anudeep T.C., Jain R., Swati K., Jha N.K., Sharma A., Kesari K.K., et al. Fostering mesenchymal stem cell therapy to halt cytokine storm in COVID-19. Biochim. Biophys. Acta Mol. Basis Dis. 2021;1867:166014. doi: 10.1016/j.bbadis.2020.166014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2020.166014</ArticleId><ArticleId IdType="pmc">PMC7680525</ArticleId><ArticleId IdType="pubmed">33232817</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallis P., Michalopoulos E., Chatzistamatiou T., Stavropoulos-Giokas C. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection. World J. Stem Cells. 2020;12:731&#x2013;751. doi: 10.4252/wjsc.v12.i8.731.</Citation><ArticleIdList><ArticleId IdType="doi">10.4252/wjsc.v12.i8.731</ArticleId><ArticleId IdType="pmc">PMC7477656</ArticleId><ArticleId IdType="pubmed">32952855</ArticleId></ArticleIdList></Reference><Reference><Citation>Gur-Wahnon D., Borovsky Z., Beyth S., Liebergall M., Rachmilewitz J. Contact-dependent induction of regulatory antigen-presenting cells by human mesenchymal stem cells is mediated via STAT3 signaling. Exp. Hematol. 2007;35:426&#x2013;433. doi: 10.1016/j.exphem.2006.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exphem.2006.11.001</ArticleId><ArticleId IdType="pubmed">17309823</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Yin Z., Zhang R., Yan K., Chen L., Chen F., Huang W., Lv B., Sun C., Jiang X. MSCs inhibit bone marrow-derived DC maturation and function through the release of TSG-6. Biochem. Biophys. Res. Commun. 2014;450:1409&#x2013;1415. doi: 10.1016/j.bbrc.2014.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2014.07.001</ArticleId><ArticleId IdType="pubmed">25014173</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav P., Vats R., Bano A., Bhardwaj R. Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci. 2020;263:118588. doi: 10.1016/j.lfs.2020.118588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.118588</ArticleId><ArticleId IdType="pmc">PMC7547615</ArticleId><ArticleId IdType="pubmed">33049279</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal A.D., Van Elzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): An overview of biological factors that may contribute to persistent symptoms. Front. Microbiol. 2021;12:698169. doi: 10.3389/fmicb.2021.698169.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.698169</ArticleId><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Duncan G. Long COVID: Scientists and Doctors Grapple with Unanswered Questions. Mar 13, 2021.  [(accessed on 13 August 2021)].  Available online:  https://www.thenationalnews.com/uae/health/long-covid-scientists-and-doctors-grapple-with-unanswered-questions-1.1182976.</Citation></Reference><Reference><Citation>Sang L., Guo X., Shi J., Hou S., Fan H., Lv Q. Characteristics and developments in mesenchymal stem cell therapy for COVID-19: An update. Stem Cells Int. 2021;2021:5593584. doi: 10.1155/2021/5593584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5593584</ArticleId><ArticleId IdType="pmc">PMC8205583</ArticleId><ArticleId IdType="pubmed">34211556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kean T.J., Lin P., Caplan A.I., Dennis J.E. MSCs: Delivery routes and engraftment, cell-targeting strategies, and immune modulation. Stem Cells Int. 2013;2013:732742. doi: 10.1155/2013/732742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/732742</ArticleId><ArticleId IdType="pmc">PMC3755386</ArticleId><ArticleId IdType="pubmed">24000286</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustad K.C., Gurtner G.C. Mesenchymal stem cells home to sites of injury and inflammation. Adv. Wound Care. 2012;1:152. doi: 10.1089/wound.2011.0314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/wound.2011.0314</ArticleId><ArticleId IdType="pmc">PMC3623614</ArticleId><ArticleId IdType="pubmed">24527296</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala-Cuellar A.P., Kang J.H., Jeung E.B., Choi K.C. Roles of mesenchymal stem cells in tissue regeneration and immunomodulation. Biomol. Ther. 2019;27:25&#x2013;33. doi: 10.4062/biomolther.2017.260.</Citation><ArticleIdList><ArticleId IdType="doi">10.4062/biomolther.2017.260</ArticleId><ArticleId IdType="pmc">PMC6319543</ArticleId><ArticleId IdType="pubmed">29902862</ArticleId></ArticleIdList></Reference><Reference><Citation>Garc&#xed;a-Bernal D., Garc&#xed;a-Arranz M., Y&#xe1;&#xf1;ez R.M., Herv&#xe1;s-Salcedo R., Cort&#xe9;s A., Fern&#xe1;ndez-Garc&#xed;a M., Hernando-Rodr&#xed;guez M., Quintana-Bustamante &#xd3;., Bueren J.A., Garc&#xed;a-Olmo D., et al. The current status of mesenchymal stromal cells: Controversies, unresolved issues and some promising solutions to improve their therapeutic efficacy. Front. Cell Dev. Biol. 2021;9:650664. doi: 10.3389/fcell.2021.650664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.650664</ArticleId><ArticleId IdType="pmc">PMC8007911</ArticleId><ArticleId IdType="pubmed">33796536</ArticleId></ArticleIdList></Reference><Reference><Citation>Yagi H., Soto-Gutierrez A., Parekkadan B., Kitagawa Y., Tompkins R.G., Kobayashi N., Yarmush M.L. Mesenchymal stem cells: Mechanisms of immunomodulation and homing. Cell Transpl. 2010;19:667&#x2013;679. doi: 10.3727/096368910X508762.</Citation><ArticleIdList><ArticleId IdType="doi">10.3727/096368910X508762</ArticleId><ArticleId IdType="pmc">PMC2957533</ArticleId><ArticleId IdType="pubmed">20525442</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma D., Zhao F. Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. NPJ Regen. Med. 2021;6:37. doi: 10.1038/s41536-021-00147-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41536-021-00147-x</ArticleId><ArticleId IdType="pmc">PMC8245638</ArticleId><ArticleId IdType="pubmed">34193864</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X., Jiang J., Gu Z., Zhang J., Chen Y., Liu X. Mesenchymal stromal cell therapies: Immunomodulatory properties and clinical progress. Stem Cell Res. Ther. 2020;11:345. doi: 10.1186/s13287-020-01855-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01855-9</ArticleId><ArticleId IdType="pmc">PMC7414268</ArticleId><ArticleId IdType="pubmed">32771052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah M., Liu D.D., Thakor A.S. mesenchymal stromal cell homing: Mechanisms and strategies for improvement. iScience. 2019;15:421&#x2013;438. doi: 10.1016/j.isci.2019.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2019.05.004</ArticleId><ArticleId IdType="pmc">PMC6529790</ArticleId><ArticleId IdType="pubmed">31121468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ip J.E., Wu Y., Huang J., Zhang L., Pratt R.E., Dzau V.J. mesenchymal stem cells use integrin 1 not cxc chemokine receptor 4 for myocardial migration and engraftment. Mol. Biol. Cell. 2007;18:2873&#x2013;2882. doi: 10.1091/mbc.e07-02-0166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e07-02-0166</ArticleId><ArticleId IdType="pmc">PMC1949353</ArticleId><ArticleId IdType="pubmed">17507648</ArticleId></ArticleIdList></Reference><Reference><Citation>Son B.-R., Marquez-Curtis L.A., Kucia M., Wysoczynski M., Turner A.R., Ratajczak J., Ratajczak M.Z., Janowska-Wieczorek A. Migration of bone marrow and cord blood mesenchymal stem cells in vitro is regulated by stromal-derived factor-1-cxcr4 and hepatocyte growth factor-c-met axes and involves matrix metalloproteinases. Stem Cells. 2006;24:1254&#x2013;1264. doi: 10.1634/stemcells.2005-0271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/stemcells.2005-0271</ArticleId><ArticleId IdType="pubmed">16410389</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagaradze G.D., Basalova N.A., Efimenko A.Y., Tkachuk V.A. Mesenchymal stromal cells as critical contributors to tissue regeneration. Front. Cell Dev. Biol. 2020;8:576176. doi: 10.3389/fcell.2020.576176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.576176</ArticleId><ArticleId IdType="pmc">PMC7546871</ArticleId><ArticleId IdType="pubmed">33102483</ArticleId></ArticleIdList></Reference><Reference><Citation>Purcaru O.S., Artene S.A., Barcan E., Silosi C.A., Stanciu I., Danoiu S., Tudorache S., Tataranu L.G., Dricu A. The interference between SARS-CoV-2 and tyrosine kinase receptor signaling in cancer. Int. J. Mol. Sci. 2021;22:4830. doi: 10.3390/ijms22094830.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22094830</ArticleId><ArticleId IdType="pmc">PMC8124491</ArticleId><ArticleId IdType="pubmed">34063231</ArticleId></ArticleIdList></Reference><Reference><Citation>Behnke J., Kremer S., Shahzad T., Chao C.M., B&#xf6;ttcher-Friebertsh&#xe4;user E., Morty R.E., Bellusci S., Ehrhardt H. MSC based therapies&#x2014;new perspectives for the injured lung. J. Clin. Med. 2020;9:682. doi: 10.3390/jcm9030682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030682</ArticleId><ArticleId IdType="pmc">PMC7141210</ArticleId><ArticleId IdType="pubmed">32138309</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang S., Xu C., Zhang Y., Xue C., Yang C., Bi H., Qian X., Wu M., Ji K., Zhao Y., et al. Umbilical cord-derived mesenchymal stem cell-derived exosomal micrornas suppress myofibroblast differentiation by inhibiting the transforming growth factor-b/smad2 pathway during wound healing. Stem Cells Transl. Med. 2016;5:1425&#x2013;1439. doi: 10.5966/sctm.2015-0367.</Citation><ArticleIdList><ArticleId IdType="doi">10.5966/sctm.2015-0367</ArticleId><ArticleId IdType="pmc">PMC5031180</ArticleId><ArticleId IdType="pubmed">27388239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahrouf-Yorgov M., Augeul L., Da Silva C.C., Jourdan M., Rigolet M., Manin S., Ferrera R., Ovize M., Henry A., Guguin A., et al. Mesenchymal stem cells sense mitochondria released from damaged cells as danger signals to activate their rescue properties. Cell Death Differ. 2017;24:1224&#x2013;1238. doi: 10.1038/cdd.2017.51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cdd.2017.51</ArticleId><ArticleId IdType="pmc">PMC5520168</ArticleId><ArticleId IdType="pubmed">28524859</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma N., Gai H., Mei J., Ding F., Bao C., Nguyen D.M., Zhong H. Bone marrow mesenchymal stem cells can differentiate into type II alveolar epithelial cells in vitro. Cell Biol. Int. 2011;35:1261&#x2013;1266. doi: 10.1042/CBI20110026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/CBI20110026</ArticleId><ArticleId IdType="pubmed">21542803</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Ravikumar M., Ling L., Nurcombe V., Cool S.M. Age-Related Changes in the Inflammatory Status of Human Mesenchymal Stem Cells: Implications for Cell Therapy. Stem Cell Rep. 2021;16:694&#x2013;707. doi: 10.1016/j.stemcr.2021.01.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2021.01.021</ArticleId><ArticleId IdType="pmc">PMC8072029</ArticleId><ArticleId IdType="pubmed">33636113</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterman R.S., Tomchuck S.L., Henkle S.L., Henkle S.L., Betancourt A.M. A New Mesenchymal Stem Cell (MSC) Paradigm: Polarization into a Pro-Inflammatory MSC1 or an Immunosuppressive MSC2 Phenotype. PLoS ONE. 2010;5:e10088. doi: 10.1371/journal.pone.0010088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0010088</ArticleId><ArticleId IdType="pmc">PMC2859930</ArticleId><ArticleId IdType="pubmed">20436665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurte M., Vega-Letter A.M., Luz-Crawford P., Djouad F., No&#xeb;l D., Khoury M., Carri&#xf3;n F. Time-Dependent LPS Exposure Commands MSC Immunoplasticity through TLR4 Activation Leading to Opposite Therapeutic Outcome in EAE. Stem Cell Res. Ther. 2020;11:416. doi: 10.1186/s13287-020-01840-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-020-01840-2</ArticleId><ArticleId IdType="pmc">PMC7520958</ArticleId><ArticleId IdType="pubmed">32988406</ArticleId></ArticleIdList></Reference><Reference><Citation>Shammaa R., El-Kadiry A.E.H., Abusarah J., Rafei M. Mesenchymal Stem Cells Beyond Regenerative Medicine. Front. Cell Dev. Biol. 2020;8:72. doi: 10.3389/fcell.2020.00072.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2020.00072</ArticleId><ArticleId IdType="pmc">PMC7040370</ArticleId><ArticleId IdType="pubmed">32133358</ArticleId></ArticleIdList></Reference><Reference><Citation>Betancourt A.M., Waterman R.S. The Role of Mesenchymal Stem Cells in the Tumor Microenvironment. In: Biswas S., editor. Tumor Microenvironment and Myelomonocytic Cells. InTech; London, UK: 2012. pp. 255&#x2013;286.</Citation></Reference><Reference><Citation>Li L., Li J., Gao M., Fan H., Wang Y., Xu X., Chen C., Liu J., Kim J., Aliyari R., et al. Interleukin-8 as a Biomarker for Disease Prognosis of Coronavirus Disease-2019 Patients. Front. Immunol. 2020;11:602395. doi: 10.3389/fimmu.2020.602395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.602395</ArticleId><ArticleId IdType="pmc">PMC7820901</ArticleId><ArticleId IdType="pubmed">33488599</ArticleId></ArticleIdList></Reference><Reference><Citation>Mushahary D., Spittler A., Kasper C., Weber V., Charwat V. Isolation, Cultivation, and Characterization of Human Mesenchymal Stem Cells. Cytom. Part A. 2017;93:19&#x2013;31. doi: 10.1002/cyto.a.23242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.a.23242</ArticleId><ArticleId IdType="pubmed">29072818</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui E., Funaki S., Kimura K., Momozane T., Kimura A., Chijimatsu R., Kanzaki R., Kanou T., Ose N., Minami M., et al. Adipose Tissue-Derived Stem Cells Have the Ability to Differentiate into Alveolar Epithelial Cells and Ameliorate Lung Injury Caused by Elastase-Induced Emphysema in Mice. Stem Cells Int. 2019;2019:5179172. doi: 10.1155/2019/5179172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/5179172</ArticleId><ArticleId IdType="pmc">PMC6590553</ArticleId><ArticleId IdType="pubmed">31281377</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Huang H., Lu X., Yan X., Jiang X., Xu R., Wang S., Zhang C., Yuan X., Xu Z., et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: A randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct. Target. Ther. 2021;6:58. doi: 10.1038/s41392-021-00488-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00488-5</ArticleId><ArticleId IdType="pmc">PMC7873662</ArticleId><ArticleId IdType="pubmed">33568628</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalan N., Nor S.N.M., Mohamed M.S. Regulation of stem cell technology in malaysia: Current status and recommendations. Sci. Eng. Ethics. 2020;26:1&#x2013;25. doi: 10.1007/s11948-019-00111-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11948-019-00111-5</ArticleId><ArticleId IdType="pubmed">31123979</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health Malaysia  National Standards for Stem Cell Transplantation: Collection, Processing, Storage and Infusion of Hematopoietic Stem Cells and Therapeutic Cells.  [(accessed on 27 August 2021)]; Available online:  https://www.moh.gov.my/moh/resources/Arkib/National_Standards_For_Stem_cell_Transplatation_new.pdf.</Citation></Reference><Reference><Citation>Ministry of Health Malaysia  Malaysian Guidelines for Stem Cell Research and Therapy.  [(accessed on 23 August 2021)];2009  Available online:  https://www.crc.gov.my/wp-content/uploads/documents/MALAYSIAN%20GUIDELINES%20FOR%20STEM%20CELL%20RESEARCH%20AND%20THERAPY%202009%20.pdf.</Citation></Reference><Reference><Citation>International Society for Stem Cell Research  ISSCR Guidelines for Stem Cell Research and Clinical Translation. May, 2021.  [(accessed on 28 August 2021)].  Available online:  https://www.isscr.org/docs/default-source/all-isscr-guidelines/2021-guidelines/isscr-guidelines-for-stem-cell-research-and-clinical-translation-2021.pdf?sfvrsn=979d58b1_4.</Citation></Reference><Reference><Citation>Elstner A., Damaschun A., Kurtz A., Stacey G., Ar&#xe1;n B., Veiga A., Borstlap J. The Changing Landscape of European and International Regulation on Embryonic Stem Cell Research. Stem Cell Res. 2009;2:101&#x2013;107. doi: 10.1016/j.scr.2008.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2008.10.003</ArticleId><ArticleId IdType="pubmed">19383415</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng Z., Zhu R., Hou W., Feng Y., Yang Y., Han Q., Shan G., Meng F., Du D., Wang S., et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11:216&#x2013;228. doi: 10.14336/AD.2020.0228.</Citation><ArticleIdList><ArticleId IdType="doi">10.14336/AD.2020.0228</ArticleId><ArticleId IdType="pmc">PMC7069465</ArticleId><ArticleId IdType="pubmed">32257537</ArticleId></ArticleIdList></Reference><Reference><Citation>Merck &amp;, Co.  Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults.  [(accessed on 28 October 2021)].  Available online:  https://www.merck.com/news/merck-and-ridgeback-announce-initiation-of-a-rolling-review-by-the-european-medicines-agency-for-molnupiravir-an-investigational-oral-antiviral-medicine-for-the-treatment-of-covid-19-in-adults/</Citation></Reference><Reference><Citation>Merck &amp;, Co.  Merck and Ridgeback&#x2019;s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.  [(accessed on 28 October 2021)].  Available online:  https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/</Citation></Reference><Reference><Citation>Nowakowski A., Walczak P., Lukomska B., Janowski M. Genetic engineering of mesenchymal stem cells to induce their migration and survival. Stem Cells Int. 2016;2016:4956063. doi: 10.1155/2016/4956063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/4956063</ArticleId><ArticleId IdType="pmc">PMC4868914</ArticleId><ArticleId IdType="pubmed">27242906</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>